Additional Titles:
Director, Lymphoma Program
Director, Fellowship Program
Clinical Interests:
Lymphoma, cancer immunotherapy, hematopoietic stem cell transplantation
Research Interests:
Tumor immunology, biology of natural killer cells
Education and Training:
Fellowship: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Residency: University of Chicago, Chicago, IL
M.D.: University of Chicago-Pritzker, Chicago, IL
Board Certifications:
Internal Medicine
Oncology
Recent Publications:
- Robertson MJ, Kirkwood JM, Logan T, Koch KM, Kathman S, Pandite LN, Kirby LC, Bell WN, Thurmond LM, Weisenbach J, Blair H, Dar MM. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res. 2008; 14: 3462-3469.
- Robertson MJ. Evaluation of the immunological effects of cytokines administered to patients with cancer. In: House RV, Descotes J, eds. Cytokines in Human Health: Immunotoxicology, Pathology, and Therapeutic Applications. Totowa, NJ: Humana Press 2007: 297-317
- Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, LaCasce A, Thornton D, Slapak CA, Shipp MA. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed and refractory diffuse large B-cell lymphoma. J Clin Oncol. 2007; 25: 1741-1746
- Starnes T, Rasila KK, Robertson MJ, Brahmi Z, Dahl R, Christopherson K, Hromas R. The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implication for the down-regulation of CXCL14 in malignancy. Exp Hematol. 2006; 34: 1101-1105.
- Sreedharan A, Bowyer S, Wallace CA, Robertson MJ, Schmidt K, Woolfrey AE, Nelson RP Jr. Macrophage activation syndrome and other systemic inflammatory conditions after BMT. Bone Marrow Transplant. 2006; 37: 629-634
- Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J, Li S, Weller EA, Orazi A, Horning SJ. Rituximab, bevacizumab, and CHOP (RA-CHOP) in untreated diffuse large B cell lymphoma: safety, biomarker, and pharmacokinetic analysis. Leukemia and Lymphoma 2006; 47: 998-1005
- Robertson MJ, Mier JW, Logan T, Atkins M, Koon H, Koch KM, Kathman S, Pandite LN, Oei C, Kirby LC, Jewell RC, Bell WN, Thurmond LM, Weisenbach J, Roberts S, Dar MM. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res. 2006; 12: 4265-4273
- Logan TF, Robertson MJ. Interleukins 18 and 21: biology, mechanisms of action, toxicity, and clinical activity. Current Oncol Reports 2006; 8: 114-119.
- Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006; 24: 4867-4874
- Robertson MJ, Abonour R, Hromas R, Nelson RP, Fineberg NS, Cornetta K. Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin?s lymphoma. Leukemia and Lymphoma 2005; 46: 1477-1487
- Ganjoo KN, Robertson MJ, Fisher W, Jung SH, McClean J, Huh SY, Bufill J, Williams S, Cripe LD. Phase II study of single agent gemcitabine in relapsed or refractory low grade non-Hodgkin's lymphoma. Am J Clin Oncol. 2005; 28: 169-172.
- Robertson MJ, Schacterle RS, Mackin GA, Wilson SN, Bloomingdale KL, Ritz J, Komaroff AL. Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis, and major depression. Clin Exp Immunol. 2005; 141: 325-332.
- Robertson MJ, Chang HC, Pelloso D, Kaplan MH. Impaired intereron-gamma production as a consequence of STAT4 deficiency after autologous stem cell transplantation for lymphoma. Blood 2005; 106: 963-970.
- Robertson MJ. Role of chemokines in the biology of natural killer cells. J Leukoc Biol. 2002; 71: 173-183
- Robertson MJ, Pelloso D, Abonour R, Hromas RA, Nelson RP, Wood L, Cornetta K. Interleukin-12 immunotherapy after autologous stem cell transplantation. Clin. Cancer Res. 2002; 8: 3383-3393.
- Robertson MJ, Bierman P, Bolwell BJ, Shea TC, Pecora AL, Mann L, Fox V, McAfee S. Safety and biologic activity of siplizumab in non-myeloablative allogeneic peripheral blood stem cell transplantation for refractory non-Hodgkin's lymphoma. Blood 2002; 100: 426a.
|
